GBSN-15c-TWO FDA approvals coming this month per the ceo in a CC last week. Stock has been hammered because of bad financing, but the dilution is over and the OS is still only 110 M. There is a meeting for a RS at the end of the month, but plenty of time for a big run. Chart is setting up very nice as well. One FDA approval takes this over 50 cents. Two? Blue skies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.